Business
HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM
PLYMOUTH MEETING, Pa., Aug. 1, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"text","content":"PLYMOUTH MEETING, Pa., Aug. 1, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (\"Harmony\" or the \"Company\") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that its Board of Directors authorized the repurchase of up to $125 million of the Company's common stock.\n\n \n \n \n \n \n \n\n \n\"Our strong balance sheet and cash generation provides us with the flexibility to return capital to shareholders while continuing to execute on and advance our growth strategy,\" said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony. \"This share repurchase program reflects the confidence of the Board and management in the strength of the company, conviction in our long-term growth potential, and our commitment to deploy capital to maximize shareholder value.\"\nThe timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of the shares of the Company's common stock and general market conditions. Share repurchases under the program may be made from time to time through a variety of methods, which may include open market purchases, block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The program does not obligate the Company to acquire any particular amount of its common stock, and the share repurchase program may be modified, suspended or discontinued at any time without notice.\nAbout Harmony BiosciencesAt Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com. \nForward Look...